fda warning about semaglutide approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease FDA Ozempic Warning | Ozempic

Its ability to interact with multiple melanocortin receptors allows for broader analysis of signaling behavior compared to more selective analogs

Cisplatin nephrotoxicity: mechanisms and renoprotective strategies

In the SELECT trial, patients did not enroll for the specific purpose of weight loss and received standard of care covering management of CV risk factors, including medical treatment and healthy lifestyle counseling, but without a specific focus on weight loss

Internal Support for Skin Health Sometimes the best approach starts from within

"Long-Term Outcomes of Integrated Weight Management Programs." Published February 2026

This became the basis for exenatide, the first GLP-1 receptor agonist medication approved in 2005